SWX:NOVNPharmaceuticals
Should Cosentyx's Phase III Success in Polymyalgia Rheumatica Prompt Action From Novartis (SWX:NOVN) Investors?
Novartis recently announced that Cosentyx met all primary and secondary endpoints in the Phase III REPLENISH trial, showing statistically significant and clinically meaningful sustained remission at Week 52 for adults with polymyalgia rheumatica.
This achievement highlights the company's momentum in late-stage innovation, as similar positive clinical outcomes were reported across other major therapies in immunology, oncology, and rare diseases.
Next, we'll explore how Cosentyx's late-stage...